Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Operating Leases (2020 - 2025)

Historic Operating Leases for Revolution Medicines (RVMD) over the last 6 years, with Q3 2025 value amounting to $142.1 million.

  • Revolution Medicines' Operating Leases rose 8150.3% to $142.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.1 million, marking a year-over-year increase of 8150.3%. This contributed to the annual value of $123.0 million for FY2024, which is 5261.68% up from last year.
  • Latest data reveals that Revolution Medicines reported Operating Leases of $142.1 million as of Q3 2025, which was up 8150.3% from $119.7 million recorded in Q2 2025.
  • Revolution Medicines' Operating Leases' 5-year high stood at $142.1 million during Q3 2025, with a 5-year trough of $26.8 million in Q3 2021.
  • Its 5-year average for Operating Leases is $72.3 million, with a median of $59.6 million in 2022.
  • Over the last 5 years, Revolution Medicines' Operating Leases had its largest YoY gain of 28219.64% in 2021, and its largest YoY loss of 957.9% in 2021.
  • Over the past 5 years, Revolution Medicines' Operating Leases (Quarter) stood at $60.4 million in 2021, then fell by 4.94% to $57.4 million in 2022, then skyrocketed by 40.3% to $80.6 million in 2023, then surged by 52.62% to $123.0 million in 2024, then grew by 15.58% to $142.1 million in 2025.
  • Its Operating Leases was $142.1 million in Q3 2025, compared to $119.7 million in Q2 2025 and $121.4 million in Q1 2025.